Entering text into the input field will update the search result below

PLC Systems Inc. (PLCSF) Appoints Susan Papalia, RN, BSN, Vice President of Clinical Affairs

May 18, 2011 10:52 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

Located in Franklin, Mass, PLC has quickly earned a stellar reputation as a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Today, PLC took a major step towards prominence with the announcement they have added Susan Papalia, RN, BSN, as their Vice President of Clinical Affairs.

In her new role, Papalia will be responsible for overseeing and leading the U.S. clinical study of PLC’s RenalGuard. In only a short period of time, RenalGuard has obtained the CE Mark in the European Union. PLC now plans to commence the pivotal trial in the U.S. to seek approval for sales and marketing from the U.S. Food and Drug Administration (FDA).

Leading the team at PLC Medical Systems is Mark R. Tauscher whom serves as the President and Chief Executive Officer. Commenting on the impact of having Susan Papalia undertake this new role, Tauscher was quoted as saying, “Susan brings to PLC more than 20 years of experience in clinical research and regulatory approvals related to the launch of new medical devices in the U.S. and international markets. With her expertise and our innovative technology, we are looking forward to the first subject enrollments in the U.S. pivotal trial for RenalGuard. We are confident that the results will confirm the effectiveness of RenalGuard and the associated RenalGuard Therapy in reducing the incidence of Contrast-Induced Nephropathy (CIN) in at-risk patients, as already demonstrated in the results from the investigator-sponsored REMEDIAL II and MYTHOS clinical trials in Italy.”

Currently, PLC Medical Services is trading in the $0.15 range. With the addition of Papalia and the overall market expansion of the company, PLC Medical Services is a company that savvy investors will consider placing into their portfolio.

To learn more about the company as a whole, visit the corporate website at: plcmed.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.